Should Physicians Recommend Replacing Opioids With Cannabis? Keith Humphreys PhD, Richard Saitz, MD, MPH JAMA, 2019, 321, 7, 639-640. doi : 10.1001/jama.2019.0077 https://jamanetwork.com/journals/jama/fullarticle/2723649 Recent state regulations (eg, in New York, Illinois) allow medical cannabis as a substitute for opioids for chronic pain and for addiction. Yet the evidence regarding safety, efficacy, and comparative effectiveness is at best equivocal for the former recommendation and strongly suggests the latter—substituting cannabis for opioid addiction treatments is potentially harmful. Neither recommendation meets the standards of rigor desirable for medical treatment decisions. Résumé : States that permit medical marijuana as an alternative to opioids for chronic pain and for addiction [...]
Lire la suiteThe Need for Federal Regulation of Marijuana Marketing John W. Ayers, PhD, Theodore Caputi, Eric C. Leas, PhD,MPH JAMA, June 11, 2019 Volume 321, Number 22 doi:10.1001/jama.2019.4432 A national for-profit marijuana industry is expanding substantially in the United States. Thirty-three states have legalized medical marijuana, 10 of which (where 1 in 4 individuals reside) have also legalized recreational marijuana. Sales of marijuana are projected to increase from $8.5 billion to $75 billion by 2030, rivaling current tobacco sales ($125 billion).1 The initial marijuana marketplace was limited to a few states, but emerging brands have developed sophisticated national marketing campaigns that could potentially have an [...]
Lire la suite